A patient in Pfizer’s (PFE) trial of its hemophilia drug Hympavzi died from a thrombotic stroke, Elizabeth Cairns of Endpoints News reports. The death may raise concerns that the drug could have prompted a clot that caused the patient’s stroke, though details of the case haven’t been shared and Pfizer didn’t say there was a link, according to the report.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Moderately bullish activity in Pfizer with shares up 0.14%
- Government deals lift overhang on pharma group, says BofA
- JPMorgan Quants Identify 6 Stocks at Risk of a Sharp Reversal
- Drugmakers set to make deals with Trump in exchange for incentives, WaPo reports
- Pfizer’s New Liver Cancer Trial Signals a Longer-Term Oncology Upside for PFE